Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

BMC Urology

Volumn 10, Issue , 2010, Pages

  Cardozo, Linda ^a   Khullar, Vik ^b   El Tahtawy, Ahmed ^c   Guan, Zhonghong ^c   Malhotra, Bimal ^c   Staskin, David ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FESOTERODINE; PLACEBO; BENZHYDRYL DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BLADDER; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE VOLUME; XEROSTOMIA; CLINICAL TRIAL; COMPUTER SIMULATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; URINE;

AGED; BENZHYDRYL COMPOUNDS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 77955683413     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-10-14     Document Type: Article

References (17)

1. Toviaz (fesoterodine fumarate). Full Prescribing Information. New York, NY: Pfizer Inc 2008
2. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. VW Nitti R Dmochowski PK Sand HT Forst C Haag-Molkenteller U Massow J Wang M Brodsky T Bavendam, J Urol 2007 178 6 2488 94 10.1016/j.juro.2007.08.033 17937959
3. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. C Chapple P Van Kerrebroeck A Tubaro C Haag-Molkenteller HT Forst U Massow J Wang M Brodsky, Eur Urol 2007 52 4 1204 12 10.1016/j.eururo.2007.07.009 17651893
4. Fesoterodine dose response in subjects with overactive bladder syndrome. V Khullar ES Rovner R Dmochowski V Nitti J Wang Z Guan, Urology 2008 71 5 839 43 10.1016/j.urology.2007.12.017 18342923
5. Efficacy of fesoterodine on overactive bladder symptoms in subjects with different baseline severity of urgency urinary incontinence. L Cardozo P Sand V Khullar J Wang Z Guan A Wein, Int Urogynecol J 2008 19 suppl 1 38
6. Pharmacokinetic profile of fesoterodine. B Malhotra Z Guan N Wood K Gandelman, Int J Clin Pharmacol Ther 2008 46 November 556 63 19000553
7. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. P Cole, Drugs Future 2004 29 7 715 20 10.1358/dof.2004.029.07.854168 (Pubitemid 39279145)
8. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. V Nitti M Wiatrak L Kriteman D Lipsitz, Presented at European Association of Urology: April 5-8 2006; Paris, France 2006
9. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. R Gieschke JL Steimer, Eur J Drug Metab Pharmacokinet 2000 25 1 49 58 10.1007/BF03190058 11032091
10. How modeling and simulation have enhanced decision making in new drug development. R Miller W Ewy BW Corrigan D Ouellet D Hermann KG Kowalski P Lockwood JR Koup S Donevan A El-Kattan CS Li JL Werth DE Feltner RL Lalonde, J Pharmacokinet Pharmacodyn 2005 32 2 185 97 10.1007/s10928-005-0074-7 16283534
11. Neurontin (gabapentin). Full Prescribing Information. New York, NY: Parke-Davis, Division of Pfizer Inc 2009
12. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. N Zinner KC Kobashi U Ebinger A Viegas M Egermark E Quebe-Fehling P Koochaki, Int J Clin Pract 2008 62 11 1664 74 10.1111/j.1742-1241.2008.01893.x 18811599
13. Pharmacokinetic models for the saturable distribution of paclitaxel. MO Karlsson V Molnar A Freijs P Nygren J Bergh R Larsson, Drug Metab Dispos 1999 27 10 1220 3 10497151
14. Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. W Zhang Y Song X He H Huang B Xu J Song, Neurourol Urodyn 2006 25 7 717 21 10.1002/nau.20293 16944449
15. Urinary retention and post-void residual urine in men: separating truth from tradition. SA Kaplan AJ Wein DR Staskin CG Roehrborn WD Steers, J Urol 2008 180 1 47 54 10.1016/j.juro.2008.03.027 18485378
16. Evaluation of voiding dysfunction and measurement of bladder volume. CE Kelly, Rev Urol 2004 6 Suppl 1 32 7 16985853
17. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? E Martin-Merino LA Garcia-Rodriguez EL Masso-Gonzalez CG Roehrborn, J Urol 2009 182 4 1442 8 10.1016/j.juro.2009.06.051 19683302